97 related articles for article (PubMed ID: 21463196)
1. Chronic myeloid leukemia lysate-loaded dendritic cells induce T-cell responses towards leukemia progenitor cells.
Westers TM; van den Ancker W; Bontkes HJ; Janssen JJ; van de Loosdrecht AA; Ossenkoppele GJ
Immunotherapy; 2011 Apr; 3(4):569-76. PubMed ID: 21463196
[TBL] [Abstract][Full Text] [Related]
2. Testing the safety of clinical-grade mature autologous myeloid DC in a phase I clinical immunotherapy trial of CML.
Litzow MR; Dietz AB; Bulur PA; Butler GW; Gastineau DA; Hoering A; Fink SR; Letendre L; Padley DJ; Paternoster SF; Tefferi A; Vuk-Pavlović S
Cytotherapy; 2006; 8(3):290-8. PubMed ID: 16793737
[TBL] [Abstract][Full Text] [Related]
3. Imatinib mesylate minimally affects bcr-abl+ and normal monocyte-derived dendritic cells but strongly inhibits T cell expansion despite reciprocal dendritic cell-T cell activation.
Boissel N; Rousselot P; Raffoux E; Cayuela JM; Soulier J; Mooney N; Charron D; Dombret H; Toubert A; Rea D
J Leukoc Biol; 2006 Apr; 79(4):747-56. PubMed ID: 16461746
[TBL] [Abstract][Full Text] [Related]
4. Vaccination with autologous non-irradiated dendritic cells in patients with bcr/abl+ chronic myeloid leukaemia.
Westermann J; Kopp J; van Lessen A; Hecker AC; Baskaynak G; le Coutre P; Döhner K; Döhner H; Dörken B; Pezzutto A
Br J Haematol; 2007 May; 137(4):297-306. PubMed ID: 17408402
[TBL] [Abstract][Full Text] [Related]
5. Recent advances in antigen-loaded dendritic cell-based strategies for treatment of minimal residual disease in acute myeloid leukemia.
van den Ancker W; van Luijn MM; Westers TM; Bontkes HJ; Ruben JM; de Gruijl TD; Ossenkoppele GJ; van de Loosdrecht AA
Immunotherapy; 2010 Jan; 2(1):69-83. PubMed ID: 20635890
[TBL] [Abstract][Full Text] [Related]
6. Dendritic cell vaccines for leukemia patients.
Schmitt A; Hus I; Schmitt M
Expert Rev Anticancer Ther; 2007 Mar; 7(3):275-83. PubMed ID: 17338648
[TBL] [Abstract][Full Text] [Related]
7. Combination of imatinib mesylate with autologous leukocyte-derived heat shock protein and chronic myelogenous leukemia.
Li Z; Qiao Y; Liu B; Laska EJ; Chakravarthi P; Kulko JM; Bona RD; Fang M; Hegde U; Moyo V; Tannenbaum SH; Ménoret A; Gaffney J; Glynn L; Runowicz CD; Srivastava PK
Clin Cancer Res; 2005 Jun; 11(12):4460-8. PubMed ID: 15958631
[TBL] [Abstract][Full Text] [Related]
8. Vaccination for leukemia.
Molldrem JJ
Biol Blood Marrow Transplant; 2006 Jan; 12(1 Suppl 1):13-8. PubMed ID: 16399579
[TBL] [Abstract][Full Text] [Related]
9. Leukemia-associated antigens as target structures for a specific immunotherapy in chronic myeloid leukemia.
Greiner J; Schmitt M
Eur J Haematol; 2008 Jun; 80(6):461-8. PubMed ID: 18284627
[TBL] [Abstract][Full Text] [Related]
10. In-vivo generation of leukaemia-derived dendritic cells.
Kolb HJ; Rank A; Chen X; Woiciechowsky A; Roskrow M; Schmid C; Tischer J; Ledderose G
Best Pract Res Clin Haematol; 2004 Sep; 17(3):439-51. PubMed ID: 15498715
[TBL] [Abstract][Full Text] [Related]
11. Antigen-Presenting Cell Characteristics of Human γδ T Lymphocytes in Chronic Myeloid Leukemia.
Sawaisorn P; Tangchaikeeree T; Chan-On W; Leepiyasakulchai C; Udomsangpetch R; Hongeng S; Jangpatarapongsa K
Immunol Invest; 2019 Jan; 48(1):11-26. PubMed ID: 30321079
[TBL] [Abstract][Full Text] [Related]
12. Immunogenic antigens as therapeutic targets against myeloid leukaemic cells.
Hofmann S; Greiner J
Leuk Res; 2010 Jul; 34(7):850-1. PubMed ID: 20359745
[TBL] [Abstract][Full Text] [Related]
13. BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells.
Brauer KM; Werth D; von Schwarzenberg K; Bringmann A; Kanz L; Grünebach F; Brossart P
Cancer Res; 2007 Jun; 67(11):5489-97. PubMed ID: 17545631
[TBL] [Abstract][Full Text] [Related]
14. Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study.
Rojas JM; Knight K; Wang L; Clark RE
Leukemia; 2007 Nov; 21(11):2287-95. PubMed ID: 17637811
[TBL] [Abstract][Full Text] [Related]
15. Vaccination with leukemia-loaded dendritic cells eradicates residual disease and prevent relapse.
Deeb D; Gao X; Jiang H; Divine G; Dulchavsky SA; Gautam SC
J Exp Ther Oncol; 2006; 5(3):183-93. PubMed ID: 16528969
[TBL] [Abstract][Full Text] [Related]
16. Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines.
Schnurr M; Galambos P; Scholz C; Then F; Dauer M; Endres S; Eigler A
Cancer Res; 2001 Sep; 61(17):6445-50. PubMed ID: 11522639
[TBL] [Abstract][Full Text] [Related]
17. Maintained immunogenicity of chronic myeloid leukemia-derived dendritic cells in the presence of imatinib mesylate: implication for vaccination regimens.
Westers TM; Janssen JJ; Houtenbos I; Snoijs NC; van de Loosdrecht AA; Ossenkoppele GJ
Leukemia; 2006 Jan; 20(1):154-7. PubMed ID: 16307013
[No Abstract] [Full Text] [Related]
18. Molecular persistence of chronic myeloid leukemia caused by donor T cells specific for lineage-restricted maturation antigens not recognizing immature progenitor-cells.
von dem Borne PA; van Luxemburg-Heijs SA; Heemskerk MH; Jedema I; Mulder A; Willemze R; Falkenburg JH
Leukemia; 2006 Jun; 20(6):1040-6. PubMed ID: 16525495
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic potential of leukemia-derived dendritic cells: preclinical and clinical progress.
Claxton DF; McMannis J; Champlin R; Choudhury A
Crit Rev Immunol; 2001; 21(1-3):147-55. PubMed ID: 11642601
[TBL] [Abstract][Full Text] [Related]
20. Peptides spanning the fusion region of Abl/Bcr are immunogenic and sensitize CD8(+) T lymphocytes to recognize native chronic myelogenous leukemia.
Wagner WM; Ouyang Q; Pawelec G
Leukemia; 2002 Nov; 16(11):2341-3. PubMed ID: 12399986
[No Abstract] [Full Text] [Related]
[Next] [New Search]
